The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is part of The Ohio State University and one of the 45 National Comprehensive Cancer hospitals. It is named after Arthur G. James, the founder, who desired a cancer hospital in Columbus, Ohio, United States.

There are 306 beds in The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C.

During the past decade, The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 6 clinical trials were completed, i.e. on average, 23.1% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 5 clinical trials were completed. i.e. 29.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C" #1 sponsor was "Merck Sharp & Dohme LLC" with 8 trials, followed by "Pfizer" with 7 trials sponsored, "Alexion" with 2 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored and "Alliance Foundation Trials, LLC." with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C" #1 collaborator was "Gynecologic Oncology Group" with 3 trials as a collaborator, "European Network for Gynaecological Oncological Trial Groups" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Eisai Inc." with 1 trials as a collaborator and "Eli Lilly and Company" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Endometrial Neoplasms" (2 trials), "Acute Lymphocytic Leukemia" (1 trials), "Acute Myeloid Leukemia" (1 trials) and "Advanced Malignancies Except Leukemia" (1 trials). Many other conditions were trialed in "The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C" in a lesser frequency.

Most popular intervention types in "The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C" are "Drug" (28 trials), "Biological" (11 trials), "Radiation" (3 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (5 trials), "Cisplatin" (4 trials), "Paclitaxel" (4 trials), "Carboplatin" (3 trials) and "Docetaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C" are 27 trials for "All" genders, 4 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C". undefined are not yet recruiting, 13 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, 5 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".